Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2022 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reduction compared to baseline in D-dimer levels of 16.8% versus 11.2% for...
March 14, 2022 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., March 14, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
September 16, 2021 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19

First international patient enrolled in BrazilTrial approximately 75% enrolledrNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTopline trial data anticipated in...
August 09, 2021 08:00 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2

WESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
August 04, 2021 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South AmericaTopline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 ...
July 07, 2021 08:00 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement

Provides exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19 and other indications WESTMINSTER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma,...
May 11, 2021 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update

Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- ARCA...
March 18, 2021 16:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update

Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 New patent issued by USPTO for use of Gencaro in treating...
November 23, 2020 08:30 ET | Source: ARCA biopharma, Inc.

AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed for COVID Associated...
June 03, 2020 09:55 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering

WESTMINSTER, Colo., June 03, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically...